88.66 0.00 (0.00%)
After hours: 4:41PM EST
|Bid||86.60 x 1000|
|Ask||90.99 x 100|
|Day's Range||86.43 - 89.27|
|52 Week Range||80.10 - 100.51|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 21, 2018 - Feb 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||110.59|
Canadian Solar, BioMarin Pharmaceutical and Monsanto are today's stocks to watch.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives BioMarin Pharmaceutical, Inc. a score of 47. Our analysis is based on comparing BioMarin Pharmaceutical, Inc. with the following peers – Ultragenyx Pharmaceutical, Inc., Shire PLC Sponsored ADR, Esperion Therapeutics, Inc., Sanofi Sponsored ADR, Sangamo Therapeutics, Inc., Alexion Pharmaceuticals, Inc., Catalyst Pharmaceuticals, Inc. and Amicus Therapeutics, Inc. ... Read more (Read more...)
The curtains have come down on one of the most-watched annual biotech conferences. The 59th annual meeting of the American Society of Hematology was held Dec. 9-12 in Atlanta. This year's meeting was ...
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.
Shares of Spark Therapeutics’ (ONCE) are down on Tuesday, continuing their decline from Monday, when it reported disappointing data that lagged rival BioMarin(BRMN). Leerink's Joseph Schwartz and Dae ...
Spark Therapeutics (ONCE) plunged 35% as investors were not impressed by the data from a phase I/II study on its Hemophilia A candidate, SPK-8011.
In 3Q17, BioMarin's (BMRN) Aldurazyme generated revenues of $22.4 million, which reflected an ~7.0% decline year-over-year and ~13.0% growth quarter-over-quarter.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for BioMarin Pharmaceutical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)
Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. Case in point: Shares of Spark Therapeutics’ (ONCE) closed down 35% on Monday, after presenting disappointing data at the American Society of Hematology's (ASH) annual meeting. Spark's data on its hemophilia A gene therapy, while showing a reduction in bleeding, showed smaller increases in levels of factor VIII--the clotting protein that patients with hemophilia are missing--than were seen by rival BioMarin (BRMN).
The American Society of Hematology's 59th annual meeting continues through Tuesday in Atlanta. Although stocks reacted to the presentation of abstracts in early November, the full presentation elicited ...
Biotech stocks were active Monday as analysts weighed in on a raft of announcements from companies attending the American Society of Hematology annual meeting.
Shares of Canadian Solar (CSIQ) are surging over 5% after CEO Shawn Qu offered to take the company private in a deal valued at at $1.07 billion. BioMarin Pharmaceutical (BMRN) is on the rise after announcing updates on an investigational gene therapy treatment for severe hemophilia. SunTrust Robinson Humphrey analyst Edward Nash raised his price target on the stock to $130.00. Monsanto (MON) shares are in focus as the seed and agro chemical giant will give cash back to US farmers who buy its weed killer XtendiMax with VaporGrip, which has been linked to crop damage.
BioMarin Pharmaceutical Inc. announced its most recent results for valoctocogene roxaparvovec at the 2017 American Society of Hemophilia event over the weekend. “We are very encouraged that our findings to date suggest a one-time infusion of valoctocogene roxaparvovec has the potential to eliminate bleeds, the need for exogenous factor VIII infusions and achieve FVIII levels in the normal range for patients with severe hemophilia A, with a very acceptable safety profile,” Hank Fuchs, President of Worldwide Research and Development at BioMarin Pharmaceutical Inc., said in a statement. BioMarin Pharmaceutical Inc. notes that its treatment for severe hemophilia performed well in all patients, even those that were subject to the lowest dosage.
New 1.5 Year Results Demonstrating 6e13 vg/kg Dose Achieved Sustained Factor VIII Levels within the Normal Range in Severe Hemophilia A for Most Patients Up to One Year Results Demonstrating 4e13 vg/kg ...
Shares of gene therapy biotech Spark Therapeutics Inc. tumbled more than 40% in early trade Monday, after it reported data from trials of a hemophilia treatment that analysts said look less competitive ...
Twenty-one analysts are tracking Alexion Pharmaceuticals in December 2017. Six of them are recommending a “strong buy,” while 12 are recommending a “buy.”